Abstract 116P
Background
RAS mutation has become an important part of assessment of patients with colorectal cancer (CRC), but its role in colorectal cancer patients with initially unresectable liver metastases has yet to be elaborated. We aim to assess the role of RAS mutation on convertion of patients with initially unresectable colorectal liver metastases (CLMs).
Methods
We identified CRC patients who initially with unresectable liver metastases during January 2012 to December 2017 in Zhongshan Hospital Fudan University. The association between RAS status of primary tumor and characteristics of patients were analyzed. Conversion rates was determined.
Results
A total of consecutive 433 CLM patients with available RAS status were evaluated in this study, KRAS mutation rates was 41.5%, BRAF was 6.7% and NRAS was 1.6%. 258 patients were RAS wild type and 185 patients were mutant. RAS mutation were associated with right colon cancer (P = 0.006) and lymph node metastasis (P = 0.017). Among RAS wild type patients, 56.2% (145/258) received Cetuximab plus chemotherapy treatment, 7.8% (20/258) received Bevacizumab plus chemotherapy and the others received chemotherapy only. Among RAS mutant patients, 50.8% (94/185) received Bevacizumab plus chemotherapy and 49.2% (91/185) received chemotherapy only. RAS wild type patients had a better objective response rate (52.3% vs 37.3%, p = 0.011) and higher conversion rate (24.0% vs 12.4%, P = 0.002) compare with RAS mutant patients. For RAS wild type group, patients with Cetuximab plus chemotherapy, Bevacizumab plus chemotherapy and chemotherapy only have a conversion resection rate of 31.5% ,20% and 14.3% respectively P = 0.05 for RAS mutation group, Bevacizumab plus chemotherapy had a similar conversion resection rate compared with chemotherapy only (12.6% VS 11.3%, P = 0.815).
Conclusions
RAS wild type indicated a better conversion rate for patients with initially unresectable colorectal liver metastases.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
238P - Laparoscopic cytoreduction in low disease burden, advanced-stage ovarian cancers: Experience from a tertiary cancer center
Presenter: Vikas Gupta
Session: Poster display session
Resources:
Abstract
239P - Impact of counseling on patient reported sexual adjustment following chemoradiation and brachytherapy for cervical cancer
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
240P - Morbidity and mortality of cervical cancer in the Republic of Kazakhstan
Presenter: Almagul Zhabagina
Session: Poster display session
Resources:
Abstract
241P - Impact of genomic alterations and HPV genotypes on clinical outcomes of Japanese patients with locally advanced cervical cancer
Presenter: Ikumi Kuno
Session: Poster display session
Resources:
Abstract
242P - Impact of combined interstitial and intracavitary brachytherapy in locally advanced cervical cancer: A survival and toxicity profile assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
243P - Cervical cancer screening in sub-urban area of Banten and factor associated with uptake of screening
Presenter: Prio Wibisono
Session: Poster display session
Resources:
Abstract
245P - Factors influencing adherence to cryotherapy following positive VIA result as cervical cancer prevention in Temanggung, Central Java, Indonesia
Presenter: Herindita Puspitaningtyas
Session: Poster display session
Resources:
Abstract
246P - The main of reasons of advanced stage cervical cancer in Uzbekistan
Presenter: Zakhirova Nargiza
Session: Poster display session
Resources:
Abstract
247P - Role of ADC values in assessing response after chemoradiotherapy in cervix cancer and in identifying residual disease
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract
248P - Retrospective review of metastatic carcinoma of cervix from a tertiary cancer institute of south India
Presenter: Arkoprovo Halder
Session: Poster display session
Resources:
Abstract